Lobe Sciences Announces the Closing of the Previously Announced Private Placement
Lobe Sciences (OTCQB:LOBEF), a biopharmaceutical company specializing in rare and underserved diseases, has completed its previously announced non-brokered private placement. The company issued 8,535,625 common shares at $0.04 per share, raising total gross proceeds of $341,425 CAD.
The securities issued will be subject to a four-month and one-day statutory hold period. The offering, initially announced on July 29th, was not registered under the U.S. Securities Act and cannot be offered or sold in the United States without registration or an applicable exemption.
Lobe Sciences (OTCQB:LOBEF), azienda biofarmaceutica specializzata in patologie rare e poco trattate, ha completato il collocamento privato non intermediato annunciato in precedenza. La societ脿 ha emesso 8.535.625 azioni ordinarie al prezzo di $0,04 per azione, raccogliendo proventi lordi complessivi di $341.425 CAD.
I titoli emessi saranno soggetti a un periodo di sospensione statutario di quattro mesi e un giorno. L鈥檕fferta, resa nota inizialmente il 29 luglio, non 猫 stata registrata ai sensi del U.S. Securities Act e non pu貌 essere offerta o venduta negli Stati Uniti senza registrazione o una deroga applicabile.
Lobe Sciences (OTCQB:LOBEF), una compa帽铆a biofarmac茅utica especializada en enfermedades raras y poco atendidas, ha completado la colocaci贸n privada sin intermediarios anunciada anteriormente. La empresa emiti贸 8.535.625 acciones ordinarias a $0,04 por acci贸n, recaudando un total bruto de $341.425 CAD.
Los valores emitidos estar谩n sujetos a un per铆odo de retenci贸n legal de cuatro meses y un d铆a. La oferta, anunciada originalmente el 29 de julio, no fue registrada conforme al U.S. Securities Act y no puede ofrecerse ni venderse en Estados Unidos sin registro o una exenci贸n aplicable.
Lobe Sciences (OTCQB:LOBEF), 頋穩 氚� 靻岇櫢 歆堩櫂鞚� 鞝勲鞙茧 頃橂姅 氚旍澊鞓れ牅鞎� 須岇偓臧� 鞚挫爠鞐� 氚滍憸頃� 欷戧皽鞚� 鞐嗠姅 靷 氚滍枆鞚� 鞕勲頄堨姷雼堧嫟. 須岇偓電� 8,535,625欤� 氤错喌欤�毳� 欤茧嫻 $0.04鞐� 氚滍枆頃橃棳 齑� $341,425 CAD鞚� 齑濎垬鞚奠潉 頇曤炒頄堨姷雼堧嫟.
氚滍枆霅� 歃濌秾鞚� 4臧滌洈 氚� 1鞚检潣 氩曥爼 氤措 旮瓣皠鞚� 鞝侅毄霅╇媹雼�. 7鞗� 29鞚检棎 觳橃潓 氚滍憸霅� 鞚措矆 瓿惦電� 氙戈淡 歃濌秾氩�(U.S. Securities Act)鞐� 霐半澕 霌彪霅橃 鞎婌晿鞙茧┌, 霌彪霅橃 鞎婈卑雮� 頃措嫻 氅挫牅臧� 鞝侅毄霅橃 鞎婋姅 頃� 氙戈淡 雮挫棎靹� 鞝滉车霅橁卑雮� 韺愲Г霅� 靾� 鞐嗢姷雼堧嫟.
Lobe Sciences (OTCQB:LOBEF), une soci茅t茅 biopharmaceutique sp茅cialis茅e dans les maladies rares et insuffisamment trait茅es, a finalis茅 son placement priv茅 non interm茅di茅 pr茅c茅demment annonc茅. La soci茅t茅 a 茅mis 8 535 625 actions ordinaires au prix de 0,04 $ par action, levant des produits bruts totaux de 341 425 $ CAD.
Les titres 茅mis seront soumis 脿 une p茅riode de blocage l茅gale de quatre mois et un jour. L鈥檕ffre, annonc茅e initialement le 29 juillet, n鈥檃 pas 茅t茅 enregistr茅e en vertu du U.S. Securities Act et ne peut 锚tre offerte ni vendue aux 脡tats-Unis sans enregistrement ou exemption applicable.
Lobe Sciences (OTCQB:LOBEF), ein biopharmazeutisches Unternehmen, das sich auf seltene und unterversorgte Erkrankungen spezialisiert hat, hat die zuvor angek眉ndigte nicht vermittelte Privatplatzierung abgeschlossen. Das Unternehmen gab 8.535.625 Stammaktien zu je $0,04 pro Aktie aus und erzielte Bruttoerl枚se in H枚he von insgesamt $341.425 CAD.
Die ausgegebenen Wertpapiere unterliegen einer gesetzlichen Haltefrist von vier Monaten und einem Tag. Das urspr眉nglich am 29. Juli angek眉ndigte Angebot wurde nicht nach dem U.S. Securities Act registriert und darf in den Vereinigten Staaten ohne Registrierung oder eine anwendbare Ausnahme nicht angeboten oder verkauft werden.
- Successfully raised $341,425 CAD through private placement
- Strengthened capital position to support development of rare disease therapeutics
- Potential dilution for existing shareholders due to issuance of 8,535,625 new shares
- Low share price of $0.04 indicates challenging market conditions
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
VANCOUVER, BC / / August 14, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved diseases, announces the closing of the non-brokered private placement (the "Offering") of up to 8,535,625 common share of the Company (each, a "Share") at a price of
Securities to be issued pursuant to the Offering will be subject to a statutory four-month and one day hold period.
None of the securities sold under the Offering have been and will not be registered under the United States Securities Act of 1933, as amended, and no such securities may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.
About Lobe Sciences Ltd.
Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) is a growth-stage biopharmaceutical company developing advanced treatments for rare and neurologically underserved conditions. Through its wholly owned subsidiary, Altemia, Inc., and majority-owned Cynaptec Pharmaceuticals, Inc., Lobe is advancing a patented lipid-based delivery platform for the treatment of Sickle Cell Disease and a proprietary oral analog of psilocin-Conjugated Psilocin鈩�-targeted for Chronic Cluster Headache and related disorders. The Company's mission is to improve patient outcomes through innovation and precision-driven science.
For further information, please contact:
Dr. Fred D. Sancilio, CEO
Lobe Sciences Ltd.
Investor and Media
[email protected]
Phone: +1 (949) 505-5623
Website:
Neither the "CSE" Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding "Forward-Looking" Information
This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: the expectation that the Company will receive all necessary approvals to complete the Offering; the expectation that the Company will complete the Offering on the terms disclosed; and the intended use of proceeds of the Offering are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should" or "would" or occur.
Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: the Company will receive all necessary approvals to complete the Offering; that the Company will complete the Offering on the terms and timing anticipated; and that the proceeds from the Offering will be used as anticipated. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that: the Company will not receive the necessary approvals to complete the Offering; that the Company will not complete the Offering on the terms disclosed, or at all; and that the Company will be unable to use the proceeds received from the Offering.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.
SOURCE: Lobe Sciences Ltd.
View the original on ACCESS Newswire
FAQ
How much did Lobe Sciences (LOBEF) raise in its August 2025 private placement?
What is the hold period for Lobe Sciences' private placement shares?
Can U.S. investors participate in Lobe Sciences' private placement?
What is the purpose of Lobe Sciences' private placement funding?
What was the price per share for Lobe Sciences' August 2025 private placement?
